Evolution of subclinical myocardial dysfunction detected by two-dimensional and three-dimensional speckle tracking in asymptomatic type 1 diabetic patients: a long-term follow-up study by Ringle, A et al.
DOI: 10.1530/ERP-17-0052
ID: 17-0052; March 2018
RESEARCH
Evolution of subclinical myocardial 
dysfunction detected by two-dimensional and 
three-dimensional speckle tracking in 
asymptomatic type 1 diabetic patients:  
a long-term follow-up study
Anne Ringle MD1,2, Anne Dornhorst FRCPath FRCP3, Michaela B Rehman MD2,4, 
Cristina Ruisanchez MD2,5 and Petros Nihoyannopoulos MD FRCP FACC FESC FAHA2
1Department of Cardiology, Hôpital Saint Philibert, GHICL, Lille, France
2Department of Cardiology, Hammersmith Hospital, Imperial College NHS Trust, London, UK
3Department of Diabetes and Endocrinology, Hammersmith Hospital, Imperial College NHS Trust, London, UK
4Department of Cardiology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France
5Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain
Abstract
Background: We sought to assess the long-term evolution of left ventricular (LV) function 
using two-dimensional (2D) and three-dimensional (3D) speckle tracking echocardiography 
(STE) for the detection of preclinical diabetic cardiomyopathy, in asymptomatic type 1 
diabetic patients, over a 6-year follow-up.
Design and methods: Sixty-six asymptomatic type 1 diabetic patients with no cardiovascular 
risk factors were compared to 26 matched healthy controls. Conventional, 2D and 3D-STE 
were performed at baseline. A subgroup of 14 patients underwent a 6-year follow-up 
evaluation.
Results: At baseline, diabetic patients had similar LV ejection fraction (60 vs 61%; P = NS), 
but impaired longitudinal function, as assessed by 2D-global longitudinal strain (GLS) 
(−18.9 ± 2 vs −20.5 ± 2; P = 0.0002) and 3D-GLS (−17.5 ± 2 vs −19 ± 2; P = 0.003). At follow-up, 
diabetic patients had worsened longitudinal function compared to baseline  
(2D-GLS: −18.4 ± 1 vs −19.2 ± 1; P = 0.03). Global circumferential (GCS) and radial (GRS) strains 
were unchanged at baseline and during follow-up. Metabolic status did not correlate 
with GLS, whereas GCS and GRS showed a good correlation, suggestive of a compensatory 
increase of circumferential and radial functions in advanced stages of the disease –  
long-term diabetes (GCS: −26 ± 3 vs −23.3 ± 3; P = 0.008) and in the presence of microvascular 
complications (GRS: 38.8 ± 9 vs 34.3 ± 8; P = 0.04).
Conclusions: Subclinical myocardial dysfunction can be detected by 2D and 3D-STE in 
type 1 diabetic patients, independently of any other cardiovascular risk factors. Diabetic 
cardiomyopathy progression was suggested by a mild decrease in longitudinal function 
at the follow-up, but did not extend to a clinical expression of the disease, as no death or 
over heart failure was reported.
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Cardiovascular disease is the major complication of 
diabetes, accounting for 50% of all diabetes mortality 
(1). This is not only due to coronary artery disease and 
associated hypertension, but also to the direct adverse 
effect of diabetes on the heart, irrespective of other 
cardiovascular risk factors, called diabetic cardiomyopathy 
(2, 3, 4). The mechanisms that lead to the development 
of diabetic cardiomyopathy are multifactorial and likely 
to act synergistically. These include hyperglycaemia, 
inducing increased oxidative stress and diversion to 
alternative metabolic pathways, increased free fatty acid 
leading to cardiac steatosis, insulin resistance, activation 
of the renin–angiotensin system, microvascular disease 
and cardiac autonomic dysfunction. The combination of 
these mechanisms results in myocardial hypertrophy and 
fibrosis. Previous studies have demonstrated subclinical 
impairment of diastolic and systolic longitudinal 
functions (5, 6, 7, 8) in diabetic patients. Findings on 
radial function were controversial, with either a decreased, 
preserved or even increased radial function (9, 10).
However, there is paucity of data relating to global and 
regional left ventricular (LV) function in type 1 diabetic 
patients over a prolonged follow-up period (11, 12). Indeed, 
most studies included type 2 diabetic patients with a 
significant proportion of other cardiovascular risk factors, 
which may represent confounding factors when trying to 
establish a link between diabetes and myocardial dysfunction. 
In addition, very few studies have assessed the progression 
of these changes over the years using deformation imaging 
(13). Deformation imaging has advanced rapidly, and two-
dimensional (2D) and three-dimensional (3D) (14, 15, 16) 
speckle tracking echocardiography (STE) are probably more 
sensitive measures than ejection fraction (LVEF) to assess 
global myocardial function.
In this study, we sought to assess global LV function 
using 2D and 3D-STE, to detect subclinical myocardial 
dysfunction in a cohort of asymptomatic type 1 diabetic 
patients with no cardiovascular risk factors or coronary 
artery disease. We also assessed the progression of 
preclinical LV dysfunction by conducting a 6-year 
follow-up evaluation in a subgroup of patients.
Methods
Patient population
Patients aged older than 18 years with isolated type 1 
diabetes were recruited from the diabetes outpatient clinic 
at Charing Cross Hospital (London). Exclusion criteria 
were recent diagnosis of diabetes (<1 year), documented 
cardiac disease, diabetic nephropathy, cardiovascular 
risk factors (hypertension, hypercholesterolemia, active 
smoking, obesity, age over 60 years).
Sixty-six patients were recruited, 22 of whom were 
initially studied in 2008 when an early pilot study 
had been undertaken, with a further 44 prospectively 
enrolled between June and September 2014. Each patient 
underwent an interview and a clinical examination to rule 
out any cardiovascular signs or symptoms, blood and urine 
laboratory tests, as well as 2D and 3D echocardiography.
They were subsequently compared with a control group 
of age- and gender-matched healthy subjects recruited 
between June and September 2014 among outpatients 
who presented for a routine echocardiography, providing 
they met the following criteria: no cardiovascular risk 
factors, no personal history of heart disease, no clinical 
history of chronic disease or chronic medication and 
normal transthoracic echocardiography.
A 6-year follow-up examination consisting of 
clinical, biological and echocardiographic assessment was 
performed on the initial subgroup of patients recruited in 
2008. Follow-up was only completed in 14. The rest were 
either lost to follow-up or refused (N = 3) to participate. 
One patient who had developed 3-vessel ischaemic heart 
disease was excluded from the analysis.
Patients’ characteristics and treatments (insulin) were 
similar in 2008 and 2014.
The local ethics committee approved the research 
protocol and informed consent was obtained from all 
subjects.
Echocardiography
A transthoracic echocardiography was performed 
using an IE33 ultrasound machine (Philips) according 
to standardised protocol. Standard 2D and Doppler 
measurements were performed according to the current 
guidelines of the European Association of Cardiovascular 
Imaging (17).
Additional images for 2D-STE were acquired at 
a frame-rate of 60–90 frames/s, during three cardiac 
cycles, and analysed using a semi-automated, vendor-
independent software (2D-CPA, TomTec Imaging 
Systems). Endocardial border was manually traced at 
end-diastole, tracked throughout the cardiac cycle 
and divided into six equal segments. Tracking quality 
was visually verified and adjusted where necessary. 
Global longitudinal strain (GLS) and strain rate (GLSR) 
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were obtained from apical 2-, 3- and 4-chamber views. 
Global radial and circumferential strain (GCS and GRS) 
and strain rates (GCSR and GRSR) were obtained from 
parasternal short-axis views at basal, mid-papillary 
and apical levels. Diastolic function was assessed using 
peak strain rate at early diastole (SRE) and the ratio of 
E wave and SRE (E/SRE), as it was suggested to be a better 
predictor of LV filling pressure in patients with preserved 
LVEF (18).
3D full volume of the LV was obtained from a single 
acquisition of 4 cardiac cycles, during breath-hold, at 
a volume rate of 20–40 volumes/s and analysed using 
TomTec 4D-LV function to assess 3D-GLS, 3D-LV volumes 
and 3D-LVEF. After adjusting the orientation of 2D planes, 
the software tracked the endocardial border. The observer 
adjusted the trace according to a visual assessment of 
tracking quality. 3D-LV strains were assessed and displayed 
as global and regional curves. Rotational motion was 
studied by twist (difference in rotation between base 
and apex) and torsion (twist divided by vertical distance 
between base and apex).
All studies (from 2008 to 2014) were performed using 
the same ultrasound machines and standardised protocol. 
All initial studies from 2008 were re-analysed in 2014 
using the same software, by the same operators.
Statistical analysis
Statistical analyses were performed using SPSS Statistics, 
version 22.0 (SPSS) and reviewed by the Department of 
Statistics of Lille University Hospital. Quantitative variables 
are expressed as mean ± s.d. if normally distributed (as 
assessed using Shapiro–Wilk test) or median (interquartile 
range) otherwise. Qualitative variables are expressed as 
frequencies and percentages.
Bivariate comparisons between the two groups 
(patients vs controls) were made using Student’s t-test for 
quantitative variables (or Mann–Whitney U test when 
non-normally distributed) and Chi-square or Fisher’s 
exact tests for qualitative variables. To study the evolution 
between baseline and follow-up, paired t-test or Wilcoxon 
signed-rank test was used as appropriate. The associations 
between 2D-STE, 3D-STE, standard echocardiography and 
metabolic status were determined by Pearson correlation 
coefficient, t-test or chi-square test according to the nature 
of data studied.
To assess intraobserver and interobserver variability, 
measurements were repeated in 55 randomly selected 
patients ≥1-week apart by the same observer, and in 
20 randomly selected patients by a second independent 
observer. Variability was expressed as percentage and 
intra-class correlation coefficients (ICC). Percentage intra-
observer and interobserver variabilities were calculated as 
the absolute difference divided by the average of the two 
measurements. Statistical testing was done at the two-
tailed α level of 0.05.
Results
Baseline
Clinical and biological characteristics at 
baseline The final population consisted of 66 
asymptomatic type 1 diabetic patients. Table 1 summarises 
clinical and biological data of diabetic and control 
populations at baseline (no significant difference, all 
P values >0.05). All patients were free from cardiovascular 
diseases or risk factors other than diabetes.
Echocardiographic characteristics at baseline No 
statistical difference between patients and controls was 
found in LV mass, dimensions or systolic function based 
on conventional echocardiography (all P values >0.05, 
Table 1). Diastolic dysfunction was more frequent in the 
diabetic group (11% vs 0%).
2D-STE analyses were conducted in all patients 
and controls (Table  1). Only longitudinal function was 
significantly reduced, with lower absolute values of GLS 
in the diabetic group. All other parameters of systolic 
myocardial deformation were not different in diabetic 
patients and controls (GCS, GRS, GLSR, GCSR, GRSR; 
Table 1).
E/SRE ratios were higher in the diabetic group, while 
SRE showed a non-significant downward trend.
Two patients and 3 controls were excluded from 
3D-STE analyses due to inadequate image quality. 3D data 
were not available for the subgroup of patients recruited 
in 2008. The assessment of 3D myocardial deformation 
was then carried out on 71% of the population 
(42 patients and 23 controls) and confirmed similar LV 
volumes and systolic function but significant impairment 
of longitudinal function in diabetic patients, as 
demonstrated by a decreased 3D-GLS in diabetic patients 
(Fig. 1 and Table 1). 3D Twist and Torsion were similar in 
patients and controls.
3D-GLS showed a good correlation with 
2D-GLS (ICC = 0.592 (0.117–0.791)) and with 3D-LVEF 
(r = −0.54; P < 0.0001).
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Correlation between STE and metabolic 
status Metabolic status was studied through 3 
parameters: the presence of microvascular complications 
of diabetes (microalbuminuria, neuropathy and/or 
retinopathy); diabetes control using HbA1c >53 mmol/
mol as a cut-off value for uncontrolled diabetes and 
diabetes duration, expressed in years and by dividing the 
population into two duration-based groups (‘short-term 
diabetes’ <10 years, ‘long-term diabetes’ >10 years).
No link was found between GLS and the coexistence 
of other microvascular complications of diabetes 
(2D-GLS: −19.3 ± 2 vs −18.8 ± 1; P = 0.21 and 3D-GLS: 
−17.2 ± 2 vs −17.8 ± 2; P = 0.31), between GLS and 
uncontrolled diabetes (2D-GLS: −18.9 ± 2 vs −18.9 ± 1; 
P = 0.99 and 3D-GLS: −17.7 ± 1 vs −17.3 ± 2; P = 0.52) or 
between GLS and diabetes duration – when expressed in 
years: 2D-GLS (r = 0.024; P = 0.85), 3D-GLS (r = 0.27; P = 0.08) 
or when dividing the population into two duration-based 
Table 1 Baseline characteristics of the study groups.
 Patients (n = 66) Controls (n = 26) P value
Clinical characteristics
 Age (years) 37.6 ± 9 35.1 ± 7 0.22
 Female (n, %) 47 (71%) 18 (69%) 0.85
 Body mass index (kg/m2) 24 ± 3 23 ± 3 0.10
 Systolic BP (mmHg) 121 ± 12 122 ± 9 0.69
 Diastolic BP (mmHg) 74 ± 9 74 ± 6 1
 Diabetes duration (years) 21 ± 12 – –
 Microvascular complication (n, %) 25 (39%) – –
 HbA1C (mmol/mol) 61 ± 12 – –
 LDL cholesterol (mmol/L) 2.4 ± 0.5 – –
 GFR (mL/min/1.73 m2) 89 ± 15 – –
Echocardiographic characteristics
 2D echocardiography
  LVEDD indexed (mm/m2) 26 ± 3 26 ± 2 0.72
  LVEDV indexed (mL/m2) 52 ± 13 55 ± 11 0.20
  LVESV indexed (mL/m2) 20 ± 5 21 ± 4 0.26
  LVEF (%) 60 ± 8 61 ± 3 0.84
  LV mass index (g/m2) 60 ± 14 58 ± 9 0.41
  LA volume indexed (mL/m2) 28 ± 7 28 ± 6 0.93
  E (cm/s) 74 ± 17 63 ± 12 0.001
  E/A ratio 1.6 ± 5 1.6 ± 4 0.66
  Mitral deceleration time (s) 202 ± 32 188 ± 28 0.06
  E′ (cm/s) 11.8 ± 2 11.9 ± 2 0.77
  E/E′ ratio 6.8 ± 2 5.6 ± 1 0.005
  S′ (cm/s) 8 ± 2 8 ± 1 0.66
 2D speckle tracking
  GLS (%) −18.9 ± 2 −20.5 ± 2 0.0002
  GCS (%) −25.4 ± 3 −26.1 ± 3 0.39
  GRS (%) 36.3 ± 9 37.6 ± 7 0.54
  GLSR (%) −1.21 ± 0.2 −1.24 ± 0.2 0.94
  GCSR (%) −1.8 ± 0.4 −1.8 ± 0,3 0.87
  GRSR (%) 2.4 ± 1 2.4 ± 0.6 0.28
  SRE (%) 1.2 ± 3 1.3 ± 3 0.24
  E/SRE 64 ± 20 50 ± 12 0.0002
 3D echocardiography and speckle tracking
  3D LVEDV indexed (mL/m2) 47 ± 8 47 ± 9 0.97
  3D LVESV indexed (mL/m2) 20 ± 4 19 ± 4 0.38
  3D LVEF (%) 57 ± 4 59 ± 4 0.16
  3D GLS (%) −17.5 ± 2 −19 ± 2 0.003
  3D Twist (°) 9.2 ± 5 10.2 ± 4 0.37
  3D Torsion (°/cm) 1.2 ± 0.6 1.3 ± 0.5 0.3
A, peak transmitral late diastolic velocity; BP, blood pressure; E, peak transmitral early diastolic velocity; E′, peak earl mitral annular velocity; GCS, global 
circumferential strain; GFR, glomerular filtration rate; GLS, global longitudinal strain; GRS, global radial strain; HbA1C, haemoglobin glycosylated; HDL, 
high-density lipoprotein; LA, left atrium; LDL, low-density lipoprotein; LVEDD, left ventricular end-diastolic diameter; LVEDV, left ventricular end-diastolic 
volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; SR, strain rate; SRE, strain rate at early diastole.
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Three-dimensional (3D) speckle tracking echocardiography assessment. (A) 38-year-old female diabetic patient with normal 3D-left ventricular volumes 
and ejection fraction, but decreased 3D-GLS. (B) Age-matched female control with normal 3D-left ventricular volumes, ejection fraction and 3D-GLS. 
EDV, end-diastolic volume; EF, ejection fraction; ESV, end-systolic volume; GLS, global longitudinal strain; SV, stroke volume.
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groups (<10 and >10  years: P = 0.82 for 2D-GLS, P = 0.47 
for 3D-GLS).
In contrast, circumferential and radial strains showed 
a good correlation and increased with the progression 
of the disease: GCS and GRS were higher when diabetes 
duration was >10  years (significant for GCS: −26.05 ± 3 
vs −23.3 ± 3; P = 0.009, borderline for GRS: 37.05 vs 
32; P = 0.05), also, GRS was higher in the presence of 
microvascular complications (38.8 ± 9 vs 34.3 ± 8; P = 0.04).
Rotational parameters non-significantly increased 
in long-term diabetes (Twist: 9.4 ± 5 vs 8.2 ± 5; P = 0.5, 
Torsion: 1.2 ± 0.6 vs 1 ± 0.6; P = 0.5).
Observer variabilities Intraobserver and 
interobserver reproducibility were excellent for 2D-GLS 
(intraobserver: ICC (95% confidence interval (CI)) 
0.974 (0.955–0.985), 2.5% variability; interobserver: ICC 
0.927 (0.818–0.971), 3.8% variability), 3D-GLS (0.967 
(0.944–0.981), 4.9%; 0.893 (0.728–0.958), 5.1%) and 
2D-GCS (0.951 (0.916–0.971), 3.9%; 0.899 (0.734–0.961), 
4.8%) and good for 2D-GRS (0.824 (0.699–0.897), 14.6%; 
0.815 (0.533–0.927), 12.3%).
Follow-up
Fourteen patients completed the 6-year follow-up 
assessment (50% female). None had developed overt 
heart failure. No cardiac or extra-cardiac death was 
reported. Clinical and echocardiographic characteristics 
at follow-up are summarised in Table 2.
LV volumes and ejection fraction remained unchanged 
at follow-up, while LV mass and relative wall thickness 
increased. Diastolic dysfunction (5 at follow-up (36%) 
vs 0 at baseline, P = 0.025) and LA dilation (4 (29%) vs 0, 
P = 0.046) were more frequent (Table 2).
Longitudinal function was modestly reduced at 
follow-up (decreased GLS, GLSR and S′ velocities), while 
GCS and GRS showed a non-significant increase (Table 2).
Discussion
In this study, we have shown that longitudinal function 
in type 1 diabetic patients is impaired compared to 
controls, independently of any other cardiovascular risk 
factor, despite having a normal ejection fraction. These 
findings were consistent regardless of the speckle tracking 
technique used and were confirmed in a 6-year follow-up 
evaluation conducted in a subgroup of patients: 2D-GLS 
at baseline, 3D-GLS at baseline and 2D-GLS at follow-up 
were all reduced. Conversely, GCS and GRS remained 
unchanged at baseline but increased during long-term 
follow-up in type 1 diabetics suggestive of a compensatory 
mechanism.
Subclinical myocardial dysfunction in asymptomatic type 
1 diabetic patients
The population in this study differs from previous data 
available, as it was only focused on isolated type 1 
diabetes. Patients with other cardiovascular risk factors 
were excluded as our aim was to identify direct adverse 
effects of diabetes on the heart, in the absence of other 
confounding factors.










 Age (years) 39 ± 7 45 ± 7 –
 Body mass index  
(kg/m2)
25 ± 3 24 ± 8 0.23
 Systolic BP (mmHg) 129 ± 15 132 ± 9 0.0001
 Diastolic BP (mmHg) 73 ± 8 77 ± 8 0.0001
 Uncontrolled 
diabetes (n, %)
5 (36%) 5 (38%) 0.56
 Microvascular 
complication (n, %)
3 (21%) 7 (50%) 0.046
 HbA1C (mmol/mol) 56 ± 13 59 ± 14 0.07
Standard echocardiography
 LVEDV indexed  
(mL/m2)
49 ± 10 46 ± 9 0.07
 LVEF (%) 62 ± 3 62 ± 2 0.49
 LV mass indexed  
(g/m2)
65 ± 17 73 ± 14 0.05
 RWT 0.36 ± 0.1 0.39 ± 0.1 0.008
 LA volume indexed 
(mL/m2)
25 ± 6 31 ± 10 0.01
 E (cm/s) 78 ± 21 77 ± 14 0.23
 E/A ratio 1.4 ± 0.4 1.3 ± 0.5 0.33
 Mitral deceleration 
time (s)
202 ± 41 210 ± 46 0.49
 E/E′ ratio 6.6 ± 1 7.3 ± 2 0.19
 S′ (cm/s) 9.4 ± 1 7.9 ± 1 0.0006
2D speckle tracking
 GLS (%) −19.2 ± 1 −18.4 ± 1 0.03
 GCS (%) −27.7 ± 3.7 −28.65 ± 4 0.85
 GRS (%) 36.3 ± 9 39.9 ± 5 0.27
 GLSR (%) −1.5 ± 0.2 −1.2 ± 0.2 0.01
 GCSR (%) −2.3 ± 0.3 −2.0 ± 0.4 0.3
 GRSR (%) 2.6 ± 0.6 2.4 ± 0.5 0.49
 SRE (%) 1.2 ± 0.2 1.2 ± 0.3 0.24
 E/SRE 62.8 ± 18 69 ± 21 0.39
BP, blood pressure; GCS, global circumferential strain; GLS, global 
longitudinal strain; GRS, global radial strain; HbA1C, haemoglobin 
glycosylated; LA, left atrium; LVEDV, left ventricular end-diastolic volume; 
RWT, relative wall thickness; SR, strain rate; SRE, strain rate at early 
diastole.
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Although experimental (19, 20, 21) and clinical 
(22, 23, 24) evidence is growing, the existence of a specific 
diabetic cardiomyopathy is still a matter of debate in 
this population (4, 25). The majority of previous studies 
(10, 13, 26) involved type 2 diabetic patients, 
with coexistence of hypertension (38–64%), 
hypercholesterolemia and obesity, relatively advanced 
mean age (up to 60 years) and a short diabetes duration 
(less than 10 years). Our population was younger (mean 
age 37) and the duration of diabetes was longer (21 years). 
Study population at baseline showed a higher proportion 
of female as lower-risk populations may show a female 
predominance (usual male to female sex ratio in diabetes 
mellitus 1:1–1.5:1). Recent studies have focused on type 
1 diabetes (11) but did not strictly exclude patients with 
additional risk factors (more than half of patients were 
smokers in the large study by Jensen and coworkers 
(11). We therefore demonstrated that in this diabetic 
population with isolated type 1 diabetes, subclinical 
myocardial dysfunction can be identified using STE.
Changes in systolic and diastolic function assessed by 2D 
and 3D-STE
Whether diastolic function highlights an early stage of 
diabetic cardiomyopathy before progressing to more 
significant systolic dysfunction has been controversial 
(5, 25). The prevalence ranges from 23 to 75% depending 
on the methods used and populations studied (46% in a 
study based on the current guidelines) (5). In the present 
study, diastolic dysfunction was more frequent in diabetic 
patients at baseline and worsened during follow-up (11% 
at baseline, 36% at follow-up). It was detected both by 
standard and STE parameters.
LV longitudinal function was impaired in diabetic 
patients at baseline and continued after a 6-year follow-up. 
This was detected by both 2D and 3D-STE, while standard 
echocardiography failed to detect any changes. These 
findings are consistent with previous studies (6, 7, 10, 26), 
suggesting that longitudinal fibres are the first affected 
by diabetic cardiomyopathy. Changes in the other 
components of myocardial deformation are less well 
established and vary across studies (9, 10, 12, 13, 27, 28). 
Baseline evaluation showed no significant changes in 
circumferential or radial function. In the 6-year follow-up 
group consisting of long-term (27 ± 10  years) and older 
(45 ± 7 years) diabetic patients, both GCS and GRS showed 
a non-significant upward trend. Rotational function 
was unchanged. Previous reports based on TDI, 2D-STE 
or magnetic resonance imaging also found preserved or 
increased twist and torsion in diabetic cardiomyopathy 
(29, 30).
Over the 6-year follow-up, systolic and diastolic 
parameters deteriorated. Despite these echocardiographic 
changes, no patient developed signs of overt heart failure 
at that point in time. Hence, the progression of preclinical 
diabetic cardiomyopathy seems to go through a long 
subclinical, asymptomatic phase and the hypothesis of 
diabetic cardiomyopathy leading to heart failure has not 
yet been clearly demonstrated in type-1 diabetics. It may 
be that a longer follow-up may be necessary or that more 
patients may be necessary.
Correlation with metabolic status
No correlation was found between longitudinal strain 
and metabolic status, whether assessed by glycaemic 
control, duration of diabetes or coexistence of 
microvascular complications. This is not in keeping 
with previous studies that reported a correlation 
between reduced longitudinal strain and uncontrolled 
diabetes (26, 31), diabetes duration (6) or 
microalbuminuria (11).
In contrast, circumferential and radial strain 
increased in more advanced stages of the disease, 
for long durations of diabetes (>10  years) and when 
other complications of diabetes were present. These 
findings are in agreement with recent paediatric studies 
(27, 32) as well as previous studies (6, 7, 9), in which 
circumferential and radial functions were preserved or 
paradoxically increased. A recent study in paediatric 
patients (31) with short-term type 1 diabetes reported 
increased GCS but not GLS in patients with higher 
blood sugar levels and suggested that hyperglycaemia-
induced increased energy turnover may lead at first to 
hyperdynamic cardiac mechanics which on the long 
term might contribute to the development of diabetic 
cardiomyopathy. Other reports (10, 12, 28) demonstrated 
a decrease of systolic strain in all directions, that could 
be interpreted as further progression of the disease. To 
balance reduced longitudinal function, compensatory 
mechanisms arise, with increased circumferential and 
radial contraction. Then, as the disease progresses, 
global myocardial dysfunction sets in, resulting in overt 
LV dysfunction. Fang and coworkers (9) analysed this 
phenomenon in terms of myocardial fibre orientation, 
suggesting that myocardial dysfunction starts in the 
endocardium (i.e. reduced longitudinal contraction) as 
opposed to preserved mid-wall fibres (i.e. circumferential 
and radial contraction).
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Comparison of speckle tracking techniques
As previously reported (33), 3D-STE was faster to 
acquire and to analyse compared to 2D-STE (one full-
volume image for 3D-STE vs 6 for 2D-STE), but required 
high-quality images to obtain accurate analyses. Both 
techniques showed a good reproducibility; as expected, it 
was slightly lower for GRS.
Limitations
The main limitation of this study was that follow-up was 
performed on a small number of patients. This was due 
to the fact that many patients were lost to follow-up and 
other refused to re-attend. However, we could demonstrate 
a significant worsening in longitudinal function over a 
6-year period.
Even though the two groups were comparable at 
baseline, the limited number of volunteers did not allow 
for strict matching of patients and controls.
Study population may not be representative of the 
general diabetic population as it was specifically selected 
in type-1 diabetics in order to identify direct adverse effects 
of diabetes on the heart independently of confounding 
factors.
The study protocol did not include a systematic stress 
test or coronary angiogram at baseline or at follow-up 
because it was not clinically indicated in this population. 
As in routine practice, we relied on a detailed interview, 
clinical examination and resting echocardiography, and 
excluded all patients presenting a history of cardiac disease 
or any cardiovascular sign or symptom. Diabetic patients 
were considered at very low probability of coronary artery 
disease based on clinical grounds and normal resting 
echocardiography.
We identified subclinical systolic and diastolic 
dysfunction in the diabetic group, but did not identify 
real cut-off values for an adverse prognosis. Clinical 
implications in terms of individual patient management 
remain to be determined.
Conclusions
Subclinical diastolic and systolic dysfunction can be 
detected by 2D and 3D-STE in type 1 diabetic patients, 
independently of any other cardiovascular risk factors. 
The progression of diabetic cardiomyopathy was suggested 
by a mild echocardiographic deterioration in longitudinal 
function after 6 years of follow-up in a smaller subgroup. 
It did not extend to a clinical expression of the disease, as 
no death or overt heart failure was reported.
Further longitudinal investigations on larger 
populations need to be conducted to explore the exact 
course of the disease and determine the indications for 
and specific nature of therapies to be prescribed.
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